Edition:
United Kingdom

Novartis AG (NOVN.S)

NOVN.S on Virt-X Level 1

79.38CHF
23 Feb 2018
Change (% chg)

CHF-0.60 (-0.75%)
Prev Close
CHF79.98
Open
CHF79.78
Day's High
CHF79.96
Day's Low
CHF79.02
Volume
4,038,117
Avg. Vol
4,988,779
52-wk High
CHF88.30
52-wk Low
CHF72.45

Chart for

About

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines... (more)

Overall

Beta: 1.05
Market Cap(Mil.): CHF219,900.80
Shares Outstanding(Mil.): 2,616.84
Dividend: 2.75
Yield (%): 3.27

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.60
EPS (TTM): -- -- --
ROI: -- 14.91 10.66
ROE: -- 16.41 14.30

BRIEF-Novartis AG Says Ultibro Breezhaler Improved Cardiac Function In COPD Patients With Lung Hyperinflation‍​

* SAYS TREATMENT WITH NOVARTIS' ULTIBRO BREEZHALER IMPROVED CARDIAC FUNCTION IN COPD PATIENTS WITH LUNG HYPERINFLATION‍​ Further company coverage: (Reporting by John Miller)

22 Feb 2018

MEDIA LINK-Novartis CEO is using data science to revolutionize its drug-development pipeline -WSJ

Note: Reuters has not verified this story and cannot vouch for its accuracy. (New York Newsroom)

19 Feb 2018

Novartis readies to auction U.S. generic pills business: sources

Switzerland's Novartis AG is preparing to auction its U.S. generic pill business, looking to shed a unit that has struggled amid fierce price competition, people familiar with the matter said on Friday.

16 Feb 2018

Novartis readies to auction U.S. generic pills business - sources

Switzerland's Novartis AG is preparing to auction its U.S. generic pill business, looking to shed a unit that has struggled amid fierce price competition, people familiar with the matter said on Friday.

16 Feb 2018

CORRECTED-Novartis readies to auction U.S. generic pills business -sources

Feb 16 Switzerland's Novartis AG is preparing to auction its U.S. generic pill business, looking to shed a unit that has struggled amid fierce price competition, people familiar with the matter said on Friday.

16 Feb 2018

BRIEF-Novartis forms alliance for treating infectious diarrheal disease

* NOVARTIS FORMS ALLIANCE TO DEVELOP MEDICINES FOR TREATING INFECTIOUS DIARRHEAL DISEASE

14 Feb 2018

Novartis gains U.S. approval for delayed MS drug

ZURICH Novartis's Sandoz division has won U.S. approval for a larger dosage of its Glatopa drug for multiple sclerosis (MS) patients, ending a costly delay that allowed rival generics makers to beat it to market.

13 Feb 2018

Novartis gains U.S. approval for delayed MS drug

ZURICH Novartis's Sandoz division has won U.S. approval for a larger dosage of its Glatopa drug for multiple sclerosis (MS) patients, ending a costly delay that allowed rival generics makers to beat it to market.

13 Feb 2018

UPDATE 2-Novartis gains U.S. approval for delayed MS drug

* U.S. pricing pressure weighing on Sandoz (Adds Teva comment, share price reaction)

13 Feb 2018

Novartis gets U.S. approval for bigger dose Glatopa MS treatment

ZURICH, Feb 13 Novartis's Sandoz division said on Tuesday it has won approval in the United States for a larger dosage of its Glatopa treatment for multiple sclerosis patients.

13 Feb 2018

Earnings vs. Estimates